

iShares NsUSBtchUETF GBP
Fund Information
Sector

Equity - Pharma Health & Biotech

Manager's Name

BlackRock Asset Management Ireland Ltd

Date Manager Appointed

Oct 2017

Launch Date

Oct 2017

Fund Size (£m)

£515.50

Yield* (See page 2)

0.00 %

XD Dates

N/A

Last Distribution

N/A (XD Date)

N/A (Pay Date)

N/A (Distribution)

OCF

0.35 %

Morningstar Analyst Rating

N/A

FE Crown Rating
Fund Aim

The Share Class is a share class of a Fund which aims to achieve a return on your investment, through a combination of capital growth and income on the Fund's assets, which reflects the return of the NASDAQ Biotechnology Index, the Fund's benchmark index (Index). The Share Class, via the Fund, aims to invest so far as possible and practicable in the equity securities (e.g. shares) that make up the Index. The Index measures the performance of companies listed on the NASDAQ Stock Market that are classified as either biotechnology companies or pharmaceutical companies, according to their Industry Classification Benchmark (ICB) and that also meet other eligibility criteria as determined by NASDAQ, Inc. (the Index Provider), including minimum market capitalisation and liquidity requirements. Securities that are liquid means that they can be easily bought or sold in the market in normal market conditions. The Index is weighted by a modified market capitalisation methodology, as determined by the Index Provider, such that the maximum weight of any Index constituent is capped at 8% and no more than five securities are at that cap. The excess weight of any capped security is distributed proportionally across the remaining constituent securities in the Index. This process is repeated, if necessary, to derive the final weights. The Fund intends to replicate the Index by holding the equity securities which make up the Index, in similar proportions to it. The investment manager may use financial derivative instruments (FDIs) (i.e. investments the prices of which are based on one or more underlying assets) to help achieve the Fund's investment objective. Your shares will be accumulating shares (i.e. income will be included in their value).

Sector: Equity - Pharma Health & Biotech

Performance


■ iShares NsUSBtchUETF GBP
 ■ Equity - Pharma Health & Biotech

Discrete Performance - 12 months to 31/12/20

	2020	2019	2018	2017	2016
Fund	22.03	19.78	-3.56	-	-
Stock Sector Average	18.33	23.41	-3.12	13.10	-9.26

Cumulative Performance to 30/06/21


	1 Yr	2 Yrs	3 Yrs	4 Yrs	5 Yrs
Fund	7.34	38.90	43.25	-	-
Stock Sector Average	20.32	41.43	46.91	55.29	75.01

Performance Analysis - Annualised 3 years


	Growth Rate %	Volatility	Alpha	Beta	Sharpe

iShares NsUSBtchUETF GBP

Fund Composition



	(%)
US Equities	90.47
UK Equities	2.65
Chinese Equities	2.49
German Equities	1.26
French Equities	0.91
Danish Equities	0.77
Belgian Equities	0.61
Irish Equities	0.20
Canadian Equities	0.17
Others	0.46



	(%)
USA	90.47
UK	2.65
China	2.49
Germany	1.26
France	0.91
Denmark	0.77
Belgium	0.61
Ireland	0.20
Canada	0.17
Others	0.46

Largest Holdings

Holdings	(%)
AMGEN INC	8.68
GILEAD SCIENCES INC	6.56
MODERNA INC	5.88
ILLUMINA INC	4.71
VERTEX PHARMACEUTICALS INC	4.66

Holdings	(%)
REGENERON PHARMACEUTICALS INC	4.16
BIOGEN INC	3.35
ALEXION PHARMACEUTICALS INC	3.05
SEAGEN INC	2.14
ASTRAZENECA PLC	2.00

* Data supplied by fund managers regarding fixed interests funds may not specify yield type. As the provision of redemption yield is an FCA regulatory requirement Novia assumes these are used.

Important Information

Performance details and yields are as at 30/06/2021. Performance figures are inclusive of net reinvested income. Source: FE. This document is designed only for professional investors and experienced advisers. The value of investments and the income gained may fluctuate. Investors may not get back the full amount invested. Past performance is not a guide to the future.